Strategy
Lilly Shuffles Staff, Cuts Thousands of Jobs
Eli Lilly is following the lead of Pfizer and J&J by restructuring its pharma division into separate business units with new leaders running each segment. The bad news is that 5,500 jobs will be left on the cutting room floor as part of the plan.

Deals
J&J Slims Down Elan Offer sans Tysabri
Elan was forced to trim $100 million off its billion-dollar deal with J&J due to a 50/50 agreement with Biogen Idec involving co-ownership of MS drug Tysabri. Now J&J is out a major drug, Elan is out a good chunk of cash, and Biogen Idec is pondering its next move.

Global
Takeda Takes on Europe
Takeda’s Dr. Erich Brunn tells Pharm Exec why now is the right time for the Japanese giant to get really serious about Europe.

Featured Story
Industry Audit 2009
Bill Trombetta expands his annual guide to stellar performance with the "Heavenly 27."

Advertisement:
"With [ACQUITY UPLC] we got some phenomenal results which we could just not do with HPLC…For us, it was a logical solution that we had to look then to putting UPLC on the front end of our mass spec systems. It would increase our throughput, up our instrument utilization, and make much more efficient use of the equipment that we have." See success stories from laboratory-dependent organizations like yours.

Roche appointed Pascal Soriot to chief operating officer of its pharmaceutical division, effective January 1, 2010 // EKR Therapeutics elected John E. Bailye, founder and former chairman of Dendrite International, to its board of directors as executive chairman // Rib-X Pharmaceuticals hired Thomas R. Kassberg as chief business officer // Spectrum hired Michael Cover as senior vice president and practice leader for disease management and Kevin Walsh as vice president of digital strategy // EnVivo Pharmaceuticals appointed Stephen J. DiPalma senior vice president and chief financial officer // Cylex appointed Brad L. Stewart to CEO and chairman of the board // Ritter Pharmaceuticals hired Howard Foyt, M.D., executive vice president, development and chief medical officer // GENova Biotherapeutics appointed Philip Gould, M.D., to its scientific advisory board //

September 23 Mining Business and Technology Best Practices: Winning Strategies for the E-Commerce Space
Wednesday, September 23, 2009 at 11:00 AM EDT

September 24 Drugs, Devices or Data—Which is Most Valuable? An Expert Panel Debates
Thursday, September 24, 2009 at 2:00 PM EDT

Advertisement:
Meet Pharma’s Best & Brightest in NYC

On Sept 30th, join 250 + top pharma execs, scientists and financiers live at the pharma industry’s version of the Nobel Prize - the Prix Galien Awards.

A great opportunity for high level networking and an authentic feel-good evening.
Finalists include drug agents from Glaxo, Novartis, Wyeth, Amgen, Schering, Pfizer and Sanofi.

Hosted by Charlie Rose and taking place in the magnificent “Whale Room” at NYC’s Museum of Natural History.

Learn More - Pharma's Proudest Night

September 21–24 5th Annual Process Excellence Week for the Service & Transactional World, Chicago, IL

September 30 Prix Galien 2009 Awards Ceremony, New York, NY

October 5–7 BioNetwork 2009: The 7th Annual Pharmaceutical-Biotech Partnering Conference, Laguna Niguel, California

October 20–21 CBI’s Leadership Summit on Global Interactions with Healthcare Providers, Arlington, VA

Pipeline Setback for Sanofi and Regeneron

Glaxo E-Mails Over Paxil Study Must Be Turned Over for Trial

Diabetes Medication May Get New Life as Cancer Treatment

Alcon to Buy Swiss Biotech Firm for up to $589 Million